Targeting cholangiocarcinoma

Cholangiocarcinoma

Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal). Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be awa...

Cholangiocarcinoma.

NK4 suppresses cholangiocarcinoma angiogenesis and invasion through targeting HIF-1α pathway

Cholangiocarcinoma (CCA) is a deadly biliary tract and hepatic malignancy with complicated genetics. This study aims to investigate the effect of hepatocyte growth factor (HGF) antagonist NK4 in inhibiting CCA cell hypoxic growth and invasion in vitro and in vivo. Human CCA cells stably transfected with NK4 (Hu-NK4) or control plasmid (Hu-Em) were treated with HGF under normoxia or hypoxia. The...

TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4

UNLABELLED Transforming growth factor β1 (TGF-β1) and miRNAs play important roles in cholangiocarcinoma progression. In this study, miR-29a level was found significantly decreased in both cholangiocarcinoma tissues and tumor cell lines. TGF-β1 reduced miR-29a expression in tumor cell lines. Furthermore, anti-miR-29a reduced the proliferation and metastasis capacity of cholangiocarcinoma cell li...

Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma

BACKGROUND The need for new therapies for cholangiocarcinoma is highlighted by their poor prognosis and refractoriness to chemotherapy. Increased production of Interleukin-6 promotes cholangiocarcinoma growth and contributes to chemoresistance by activating cell survival mechanisms. We sought to identify biologically active compounds capable of ameliorating the phenotypic effects of IL-6 expres...